Genmab A/S (GMAB) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Genmab A/S is set to announce its Q2 2025 earnings on August 7th, with expected earnings of $0.39 per share and revenue of $5.77 billion.
• The company's stock has experienced a 1.5% decline, currently trading at $22.27, with a market capitalization of $14.29 billion.
• Analysts have recently upgraded Genmab A/S's rating to "buy" and set a revised price target ranging from $37.00 to $46.00, reflecting a consensus "Moderate Buy" rating.

Genmab A/S (NASDAQ:GMAB - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Genmab A/S to post earnings of $0.39 per share and revenue of $5.77 billion for the quarter. Genmab A/S has set its FY 2025 guidance at EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. The company had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Genmab A/S Stock Up 0.9%

Shares of GMAB traded up $0.20 during mid-day trading on Monday, hitting $21.98. The stock had a trading volume of 582,114 shares, compared to its average volume of 1,446,639. The company has a market cap of $14.10 billion, a PE ratio of 12.48, a PEG ratio of 6.62 and a beta of 0.95. The company's fifty day simple moving average is $21.66 and its two-hundred day simple moving average is $20.83. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $27.94.

Wall Street Analyst Weigh In

Several brokerages have weighed in on GMAB. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. HC Wainwright reaffirmed a "buy" rating and set a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Finally, Truist Financial lifted their target price on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and an average target price of $37.80.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.